Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Hyman

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Schizophrenia Research|May 9, 2016
Parental type 2 diabetes in patients with non-affective psychosisBrian J Miller, David R Goldsmith, Nina Paletta, et al.
The Journal of Clinical Psychiatry|November 26, 2008
Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trialMark Hyman Rapaport, R Bruce Lydiard, Cornelius D Pitts, et al.
CNS Neuroscience & Therapeutics|March 19, 2010
Deficits in psychological well-being and quality-of-life in minor depression: implications for DSM-VAndrew A Nierenberg, Mark Hyman Rapaport, Pamela J Schettler, et al.
Psychotherapy and Psychosomatics|September 14, 2017
Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical StudiesChristopher E M Griffiths, Maurizio Fava, Andrew H Miller, et al.
Harvard Review of Psychiatry|November 22, 2011
The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depressionWaguih William Ishak, Khanh Ha, Nina Kapitanski, et al.
Psychotherapy and Psychosomatics|August 22, 2008
Clinical features and functioning of patients with minor depressionRobert H Howland, Pamela J Schettler, Mark Hyman Rapaport, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 12, 2023
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediatorsStefania Lamon-Fava, Minying Liu, Boadie W Dunlop, et al.
Brain, Behavior, & Immunity - Health|July 28, 2023
Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trialNaoise Mac Giollabhui, David Mischoulon, Boadie W Dunlop, et al.
The American Journal of Psychiatry|October 7, 2004
Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorderLewis L Judd, Mark Hyman Rapaport, Kimberly A Yonkers, et al.
Journal of Psychiatric Research|June 22, 2013
Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorderSteven J Garlow, Becky Kinkead, Michael E Thase, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Schizophrenia Research|May 9, 2016
Parental type 2 diabetes in patients with non-affective psychosisBrian J Miller, David R Goldsmith, Nina Paletta, et al.
The Journal of Clinical Psychiatry|November 26, 2008
Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trialMark Hyman Rapaport, R Bruce Lydiard, Cornelius D Pitts, et al.
CNS Neuroscience & Therapeutics|March 19, 2010
Deficits in psychological well-being and quality-of-life in minor depression: implications for DSM-VAndrew A Nierenberg, Mark Hyman Rapaport, Pamela J Schettler, et al.
Psychotherapy and Psychosomatics|September 14, 2017
Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical StudiesChristopher E M Griffiths, Maurizio Fava, Andrew H Miller, et al.
Harvard Review of Psychiatry|November 22, 2011
The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depressionWaguih William Ishak, Khanh Ha, Nina Kapitanski, et al.
Psychotherapy and Psychosomatics|August 22, 2008
Clinical features and functioning of patients with minor depressionRobert H Howland, Pamela J Schettler, Mark Hyman Rapaport, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 12, 2023
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediatorsStefania Lamon-Fava, Minying Liu, Boadie W Dunlop, et al.
Brain, Behavior, & Immunity - Health|July 28, 2023
Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trialNaoise Mac Giollabhui, David Mischoulon, Boadie W Dunlop, et al.
The American Journal of Psychiatry|October 7, 2004
Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorderLewis L Judd, Mark Hyman Rapaport, Kimberly A Yonkers, et al.
Journal of Psychiatric Research|June 22, 2013
Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorderSteven J Garlow, Becky Kinkead, Michael E Thase, et al.
Pageof 8